Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure
Anticancer Research · 2026
DOI: 10.21873/anticanres.18032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Eshat F Haque und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan. Hauptthemen laut MEDLINE: Pemetrexed, Mutation, Protein Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung.
Abstract (Originalsprache)
BACKGROUND/AIM: Resistance to targeted therapy limits its efficacy in non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although concurrent administration of pemetrexed (PEM) and EGFR-tyrosine kinase inhibitors (TKIs) has yielded clinical benefits, it remains unclear whether concurrent PEM influences de novo mutations in the EGFR-TKI therapy. To address this gap, we aimed to compare the time to acquired resistance and accumulation of de novo tumor mutational burden (TMB) during in vitro exposure to osimertinib (OSI) and gefitinib (GEF), as well as their respective combinations with PEM. MATERIALS AND METHODS: EGFR-mutated PC-9 cells were continuously exposed to EGFR-TKIs, alone or in combination with PEM, at equimolar concentrations. The drug concentration gradually increased to 1 and 3 μM for OSI and GEF, respectively. Whole-exome sequencing and quantitative PCR were performed to measure TMB and gene expression, respectively. RESULTS: Concurrent PEM with either OSI or GEF extended the treatment duration compared to single EGFR-TKIs, decreased the de novo accumulated TMB per treatment time, and increased the expression of POLE2, POLQ, MLH1, BRCA1, BRCA2, RAD51, and FEN1 compared to that of single EGFR-TKIs. CONCLUSION: Concurrent PEM with EGFR-TKI treatment slowed TMB accumulation rate and resistance acquisition in EGFR-mutated NSCLC compared to single EGFR-TKIs in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
- Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan okimoto@med.shimane-u.ac.jp.
Zitieren
APA
Haque, E. F., Tanino, R., Okimoto, T., Hotta, T., Okuno, T., Kono, K., Tsubata, Y., & Isobe, T. (2026). Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure. Anticancer Research. https://doi.org/10.21873/anticanres.18032
Vancouver
Haque EF, Tanino R, Okimoto T, Hotta T, Okuno T, Kono K, et al. Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure. Anticancer Research. 2026. doi:10.21873/anticanres.18032
BibTeX
@article{Haque2026,
author = {Haque, Eshat F and Tanino, Ryosuke and Okimoto, Tamio and Hotta, Takamasa and Okuno, Takae and Kono, Kento and Tsubata, Yukari and Isobe, Takeshi},
title = {Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18032}
}
EUVIMED